Needle-Free rotavirus vaccine patch enters first human tests
NCT ID NCT06962904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new rotavirus vaccine that is given through a dissolving microneedle patch on the skin, instead of a shot. The trial will enroll 50 healthy adults aged 18 to 45 to see if the vaccine is safe and whether it triggers an immune response. Participants will receive three doses of either the vaccine or a placebo patch.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CDC-9 inactivated rotavirus vaccine delivered via a dissolving microneedle patch
- What this could lead to
- If successful, this could lead to a needle-free, easier-to-use rotavirus vaccine that might be more acceptable and easier to distribute, especially in low-resource settings.
- What could go wrong
- This is a very early Phase 1 trial with only 50 healthy adults. It is designed primarily to check safety, not yet to prove the vaccine works. The vaccine may not trigger a strong enough immune response or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROTAVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory Children's Center - Vaccine Research Clinic
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.